Pain Management News

In children and teenagers, treatment with zonisamide was associated with a significant reduction in the number of monthly migraine days, particularly after at least 2 months of use, preliminary data show.

The International Headache Society recently issued a position paper that upgraded the standards for migraine prevention, providing a four-pronged framework for reassessing the goals for migraine control and prevention.

March is Traumatic Brain Injury Awareness Month, a condition that has led to permanent disability in more than 5 million individuals in the United States.

About 40% of patients in primary care have pain or illness that cannot be explained by diagnostic tests.

The Prospera SCS system for pain management relieved pain, improved sleep and reduced opioid use at 24 months, according to interim results of the BENEFIT-03 study.

The FDA has approved BrainSense, an adaptive deep brain stimulation system that can adjust therapy for Parkinson’s disease in real time based on the patient’s brain activity, according to the manufacturer.

The manufacturer of AV-101, an investigational, oral nonopioid, NMDA-targeting therapy to treat neuropathic pain, announced that it has received a U.S. patent for the treatment.

The FDA has approved Onapgo, the first subcutaneous apomorphine device to treat motor fluctuations in adults with Parkinson’s disease, according to the manufacturer.

Treatment with IV edaravone for ALS was linked to a slowing of disease-progression milestones compared with no IV edaravone treatment, results of an administrative claims analysis show.